To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG)
Clinical trial NCT05514158 · UNKNOWN
Trial details
- NCT number
- NCT05514158
- Sponsor
- RemeGen Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-09-28
- Primary completion
- 2024-05-30
- Enrollment
- 24
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.